Zhu AX - Search Results

1

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Finn RS, et al. Among authors: zhu ax. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. N Engl J Med. 2020. PMID: 32402160 Clinical Trial.

2

A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.

Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. Zhu AX, et al. Oncologist. 2005 Jun-Jul;10(6):392-8. doi: 10.1634/theoncologist.10-6-392. Oncologist. 2005. PMID: 15967833 Free article. Clinical Trial.

3

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K. Zhu AX, et al. J Clin Oncol. 2006 Apr 20;24(12):1898-903. doi: 10.1200/JCO.2005.04.9130. J Clin Oncol. 2006. PMID: 16622265 Clinical Trial.

4

Case records of the Massachusetts General Hospital. Case 13-2006. A 50-year-old man with a painful bone mass and lesions in the liver.

Zhu AX, D'Andrea AD, Sahani DV, Hasserjian RP. Zhu AX, et al. N Engl J Med. 2006 Apr 27;354(17):1828-37. doi: 10.1056/NEJMcpc069004. N Engl J Med. 2006. PMID: 16641400 No abstract available.

5

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.

Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Zhu AX, et al. Cancer. 2007 Aug 1;110(3):581-9. doi: 10.1002/cncr.22829. Cancer. 2007. PMID: 17583545 Free article. Clinical Trial.

6

Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma.

Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Zhu AX, et al. Oncologist. 2008 Feb;13(2):120-5. doi: 10.1634/theoncologist.2007-0174. Oncologist. 2008. PMID: 18305056 Free article. Clinical Trial.

7

Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.

Finn RS, Zhu AX. Finn RS, et al. Among authors: zhu ax. Expert Rev Anticancer Ther. 2009 Apr;9(4):503-9. doi: 10.1586/era.09.6. Expert Rev Anticancer Ther. 2009. PMID: 19374603 Review.

8

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

Wu J, Henderson C, Feun L, Van Veldhuizen P, Gold P, Zheng H, Ryan T, Blaszkowsky LS, Chen H, Costa M, Rosenzweig B, Nierodzik M, Hochster H, Muggia F, Abbadessa G, Lewis J, Zhu AX. Wu J, et al. Among authors: zhu ax. Invest New Drugs. 2010 Oct;28(5):670-6. doi: 10.1007/s10637-009-9286-9. Epub 2009 Jun 30. Invest New Drugs. 2010. PMID: 19565187 Clinical Trial.

9

Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.

Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX. Vora SR, et al. Among authors: zhu ax. Oncologist. 2009 Jul;14(7):717-25. doi: 10.1634/theoncologist.2009-0038. Epub 2009 Jul 6. Oncologist. 2009. PMID: 19581525 Free article.

10

A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma.

Kozyreva ON, Chi D, Clark JW, Wang H, Theall KP, Ryan DP, Zhu AX. Kozyreva ON, et al. Among authors: zhu ax. Oncologist. 2011;16(3):310-8. doi: 10.1634/theoncologist.2010-0223. Epub 2011 Feb 24. Oncologist. 2011. PMID: 21349948 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

391 results

Search Page